228 related articles for article (PubMed ID: 11448085)
1. Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine.
Wilton LV; Heeley EL; Pickering RM; Shakir SA
J Psychopharmacol; 2001 Jun; 15(2):120-6. PubMed ID: 11448085
[TBL] [Abstract][Full Text] [Related]
2. QTc interval prolongation and antipsychotic drug treatments: focus on sertindole.
Lindström E; Farde L; Eberhard J; Haverkamp W
Int J Neuropsychopharmacol; 2005 Dec; 8(4):615-29. PubMed ID: 15963244
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis.
Czekalla J; Beasley CM; Dellva MA; Berg PH; Grundy S
J Clin Psychiatry; 2001 Mar; 62(3):191-8. PubMed ID: 11305706
[TBL] [Abstract][Full Text] [Related]
4. Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics.
Czekalla J; Kollack-Walker S; Beasley CM
J Clin Psychiatry; 2001; 62 Suppl 2():35-40. PubMed ID: 11232751
[TBL] [Abstract][Full Text] [Related]
5. The European post-marketing observational sertindole study: an investigation of the safety of antipsychotic drug treatment.
Kasper S; Möller HJ; Hale A
Eur Arch Psychiatry Clin Neurosci; 2010 Feb; 260(1):59-68. PubMed ID: 19455275
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials.
Leucht S; Pitschel-Walz G; Abraham D; Kissling W
Schizophr Res; 1999 Jan; 35(1):51-68. PubMed ID: 9988841
[TBL] [Abstract][Full Text] [Related]
7. Biases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: the example of sertindole.
Moore N; Hall G; Sturkenboom M; Mann R; Lagnaoui R; Begaud B
Pharmacoepidemiol Drug Saf; 2003 Jun; 12(4):271-81. PubMed ID: 12812006
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, cardiac safety and tolerability of sertindole: a drug surveillance.
Pezawas L; Quiner S; Moertl D; Tauscher J; Barnas C; Küfferle B; Wolf R; Kasper S
Int Clin Psychopharmacol; 2000 Jul; 15(4):207-14. PubMed ID: 10954060
[TBL] [Abstract][Full Text] [Related]
9. Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP).
Thomas SH; Drici MD; Hall GC; Crocq MA; Everitt B; Lader MH; Le Jeunne C; Naber D; Priori S; Sturkenboom M; Thibaut F; Peuskens J; Mittoux A; Tanghøj P; Toumi M; Moore ND; Mann RD
Acta Psychiatr Scand; 2010 Nov; 122(5):345-55. PubMed ID: 20384598
[TBL] [Abstract][Full Text] [Related]
10. Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia.
Layton D; Harris S; Wilton LV; Shakir SA
J Psychopharmacol; 2005 Sep; 19(5):473-82. PubMed ID: 16166184
[TBL] [Abstract][Full Text] [Related]
11. Sertindole: dilemmas for its use in clinical practice.
Pae CU
Expert Opin Drug Saf; 2013 May; 12(3):321-6. PubMed ID: 23432404
[TBL] [Abstract][Full Text] [Related]
12. Sertindole: new drug. Another "atypical" neuroleptic; QT prolongation.
Prescrire Int; 2007 Apr; 16(88):59-62. PubMed ID: 17458045
[TBL] [Abstract][Full Text] [Related]
13. The effect of sertindole on QTD and TPTE.
Nielsen J; Andersen MP; Graff C; Kanters JK; Hardahl T; Dybbro J; Struijk JJ; Meyer JM; Toft E
Acta Psychiatr Scand; 2010 May; 121(5):385-8. PubMed ID: 20085555
[TBL] [Abstract][Full Text] [Related]
14. Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia.
Kasper S; Hale A; Azorin JM; Möller HJ
Eur Arch Psychiatry Clin Neurosci; 1999; 249 Suppl 2():II1-II14. PubMed ID: 10603070
[No Abstract] [Full Text] [Related]
15. Antipsychotic drugs and QT interval prolongation.
Zareba W; Lin DA
Psychiatr Q; 2003; 74(3):291-306. PubMed ID: 12918603
[TBL] [Abstract][Full Text] [Related]
16. Novel antipsychotics: comparison of weight gain liabilities.
Wirshing DA; Wirshing WC; Kysar L; Berisford MA; Goldstein D; Pashdag J; Mintz J; Marder SR
J Clin Psychiatry; 1999 Jun; 60(6):358-63. PubMed ID: 10401912
[TBL] [Abstract][Full Text] [Related]
17. Effect of sertindole on QTc interval in patients with schizophrenia.
Atmaca M; Yavuzkir M; Mermi O; Topuz M; Kanmaz E; Tezcan E
Neurosci Lett; 2008 Sep; 442(1):1-3. PubMed ID: 18639380
[TBL] [Abstract][Full Text] [Related]
18. The Sertindole Safety Survey: a retrospective analysis under a named patient use programme in Europe.
Lançon C; Toumi M; Sapin C; Hansen K
BMC Psychiatry; 2008 Jul; 8():57. PubMed ID: 18638382
[TBL] [Abstract][Full Text] [Related]
19. Cardiac effects of sertindole and quetiapine: analysis of ECGs from a randomized double-blind study in patients with schizophrenia.
Nielsen J; Matz J; Mittoux A; Polcwiartek C; Struijk JJ; Toft E; Kanters JK; Graff C
Eur Neuropsychopharmacol; 2015 Mar; 25(3):303-11. PubMed ID: 25583364
[TBL] [Abstract][Full Text] [Related]
20. Increased risk of antipsychotic-related QT prolongation during nighttime: a 24-hour holter electrocardiogram recording study.
Watanabe J; Suzuki Y; Fukui N; Ono S; Sugai T; Tsuneyama N; Someya T
J Clin Psychopharmacol; 2012 Feb; 32(1):18-22. PubMed ID: 22198445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
